TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A Swedish study of older women found that longer reproductive lifespan and menopausal hormone therapy use were associated with more favorable brain MRI measures. The observational findings do not show that estrogen exposure caused those differences or that hormone therapy prevents dementia.
A Swedish cohort study found that longer reproductive lifespan and use of menopausal hormone therapy were associated with lower cerebral small vessel disease burden and other more favorable brain MRI measures in older women. The findings, reported by Anna Marseglia and colleagues in Neurology, describe associations—not evidence that estrogen exposure prevents dementia or causes better brain health.
The researchers assessed 352 cognitively unimpaired women in the Gothenburg H70 birth cohort, all of whom had a brain MRI at age 70. A total of 286 took part in another examination five years later. Their average Mini-Mental State Examination score at the initial visit was 29.2, indicating generally normal cognitive performance. About 31% carried APOE4, a genetic variant associated with increased Alzheimer’s risk.
Researchers defined reproductive lifespan as the time from first menstruation to menopause or ovary removal. The average span was 37.1 years. A longer span was associated with 8% lower odds of having at least two signs of cerebral small vessel disease (odds ratio 0.92; 95% confidence interval 0.86-0.99). The study’s composite measure included white matter hyperintensities, lacunes, microbleeds and enlarged perivascular spaces.
Menopausal hormone therapy use was associated with lower odds of greater small vessel disease burden (odds ratio 0.41; 95% CI 0.20-0.81) and higher white matter integrity. Women reporting both oral contraceptive use during reproductive years and menopausal hormone therapy later had the lowest measured small vessel disease burden and the highest white matter integrity in the reported comparisons. Among APOE4 carriers, hormone therapy was associated with greater thickness in cortical regions commonly affected by Alzheimer’s disease. These are statistical relationships within this cohort, not proof of treatment effects.
Brain Vascular Measures in Focus
The results add to research examining whether hormonal history across a lifetime relates to brain aging, including vascular changes as well as Alzheimer’s-related measures. Small vessel disease can be assessed through MRI signs involving small blood vessels and surrounding brain tissue. Studying those changes may help researchers understand pathways associated with cognitive decline, but this study did not establish that participants’ MRI differences translated into different dementia rates.
The findings may also inform discussion of women’s dementia risk and how reproductive history is represented in brain research. An accompanying editorial by Tracy Madsen of the University of Vermont argued that endogenous and externally supplied estrogen exposure could be relevant to dementia research. The study does not, however, show that starting hormone therapy is an effective or appropriate way to reduce an individual’s risk.
That distinction matters because hormone therapy’s benefits and risks have been debated for decades. The results are evidence for further investigation, not a basis for changing treatment decisions. Individual decisions about hormone therapy require discussion with a qualified health professional, taking personal medical history and the treatment’s known risks into account.
Products Worth Considering
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Hyperice Hypervolt Go 3 Portable Percussion Massage Gun with Carry Case
Therabody Theragun Mini 3rd Gen Massage Gun (Travel Essential, Black)
As an affiliate, we earn on qualifying purchases.
A Debate Shaped by Earlier Trials
Earlier research raised hopes that menopausal hormone therapy might protect against Alzheimer’s disease or cardiovascular disease. But the Women’s Health Initiative Memory Study reported in 2003 that estrogen-plus-progestin treatment increased probable dementia risk among women aged 65 and older. The broader Women’s Health Initiative also linked combined therapy with increased breast cancer and heart disease risks. Those findings led to boxed warnings, which the source report says the FDA removed in 2026.
Subsequent research has examined whether outcomes differ by formulation, age or timing of treatment. The source report cites autopsy and other studies linking estrogen-only therapy with lower Alzheimer’s neuropathology, as well as a large UK Biobank study that associated earlier hormone therapy initiation with lower dementia risk. Those studies do not settle whether therapy prevents dementia, and they do not make results from one population directly applicable to every patient.
In the Gothenburg cohort, 72.7% reported oral contraceptive use and 60.8% reported menopausal hormone therapy use. The researchers relied on participants’ reports of hormonal exposure. They also acknowledged that the study lacked detailed information about the specific duration and patterns of oral contraceptive and hormone therapy use.
“The lifetime risk of dementia in U.S. women exceeds that of men.”
— Tracy Madsen, University of Vermont, in an accompanying editorial
Limits of the Hormone Evidence
The study was observational, so it cannot determine whether estrogen exposure caused the brain MRI findings. Other differences between women who did and did not use hormone therapy may help explain the associations. The findings also come from a particular Swedish cohort and may not apply to all women or treatment regimens.
Exposure information was self-reported and could be affected by recall errors or misclassification. Researchers lacked detailed data about hormone formulations, timing and duration. The study measured MRI features and cognitive test performance; it did not establish that the reported associations reduced dementia diagnoses or improved daily functioning. The source report does not provide evidence that hormone therapy should be started to protect brain health.
Further Follow-Up and Replication
Researchers will need to test these associations in other populations and studies with more detailed records of hormone type, timing and duration. Longer follow-up could help determine whether MRI differences are associated with later changes in cognition or dementia diagnoses. The Gothenburg cohort already included a five-year follow-up for 286 women, but the reported findings do not establish a treatment effect or a dementia-prevention benefit.
For now, the development is a research finding that adds reproductive and hormonal history to questions about brain aging. Any clinical implications remain unconfirmed; treatment decisions should be made with a qualified health professional rather than inferred from this cohort study.
Key Questions
What did the Swedish study find?
It found associations between longer reproductive lifespan and lower odds of greater cerebral small vessel disease burden. Menopausal hormone therapy use was also associated with lower burden and higher white matter integrity on brain measures.
Does the study show that hormone therapy prevents dementia?
No. The study was observational and reported associations with MRI measures. It did not establish that hormone therapy caused those findings or prevented dementia.
Who took part in the research?
The analysis included 352 cognitively unimpaired women from a Swedish cohort who had brain MRI at age 70. A total of 286 attended a follow-up examination five years later.
What are the main limitations?
Hormone exposure was self-reported, which can lead to recall errors or misclassification. Researchers also lacked detailed information about treatment type and use patterns, and the cohort study cannot establish cause and effect.
Source: medpagetoday.com
